Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milatuzumab in Refractory CLL
NCT00868478Phase 2Unknown
- Sponsor
- Kaplan Medical Center
- Start
- Apr 2009
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of milatuzumab in chronic lymphocytic leukemia (CLL), sponsored by Kaplan Medical Center. Status: unknown.
02
Drugs
milatuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00868478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00868478.